Inno-206
Ovarian Diseases
Astellas Pharma IncPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Ovarian Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Xiaoxiang Chen | Phase 3 | BB |
Carboplatin Fujian Cancer Hospital | Phase 3 | BB |
Inno-206 Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | BB |
Olaparib Xiaoxiang Chen | Phase 2 | BB |
Pembrolizumab Sheba Medical Center | Phase 2 | B |
View all 25 →
Same molecule, other indications
Inno-206 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →